Curis Lifescien, a company in the Pharmaceuticals industry, reported revenue of ₹34 crore and net profit of ₹4.14 crore for the September 2026 quarter.
Curis Lifescien. (NSE: CURIS-ST) closed at ₹158.00 on 20 Nov 2026. Its market capitalisation is ₹128 crore and it trades at 18.6 times earnings.
Incorporated in 2010, Curis Lifesciences Limited is a pharmaceutical company that specializes in developing, manufacturing, and distributing a diverse range of products.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.